PMID- 30635268
OWN - NLM
STAT- In-Data-Review
LR  - 20190115
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 364
DP  - 2019 Jan 11
TI  - Diabetes: precision approach will improve outcomes, says research director.
PG  - l186
LID - 10.1136/bmj.l186 [doi]
FAU - Mayor, Susan
AU  - Mayor S
AD  - London.
LA  - eng
PT  - Journal Article
DEP - 20190111
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
EDAT- 2019/01/13 06:00
MHDA- 2019/01/13 06:00
CRDT- 2019/01/13 06:00
PHST- 2019/01/13 06:00 [entrez]
PHST- 2019/01/13 06:00 [pubmed]
PHST- 2019/01/13 06:00 [medline]
AID - 10.1136/bmj.l186 [doi]
PST - epublish
SO  - BMJ. 2019 Jan 11;364:l186. doi: 10.1136/bmj.l186.

PMID- 30635275
OWN - NLM
STAT- In-Data-Review
LR  - 20190221
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 3
DP  - 2019 Mar
TI  - Erratum. Glucolipotoxicity-Inhibited miR-299-5p Regulates Pancreatic beta-Cell
      Function and Survival. Diabetes 2018;67:2280-2292.
PG  - 676
LID - 10.2337/db19-er03b [doi]
FAU - Huang, Qiqing
AU  - Huang Q
FAU - You, Weiyan
AU  - You W
FAU - Li, Yating
AU  - Li Y
FAU - Sun, Yi
AU  - Sun Y
FAU - Zhou, Yuncai
AU  - Zhou Y
FAU - Zhang, Yan
AU  - Zhang Y
FAU - Liu, Dechen
AU  - Liu D
FAU - Zhan, Shanshan
AU  - Zhan S
FAU - Zhu, Yunxia
AU  - Zhu Y
FAU - Han, Xiao
AU  - Han X
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20190111
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EFR - Diabetes. 2018 Nov;67(11):2280-2292. PMID: 30131392
EDAT- 2019/01/13 06:00
MHDA- 2019/01/13 06:00
CRDT- 2019/01/13 06:00
PHST- 2019/01/13 06:00 [pubmed]
PHST- 2019/01/13 06:00 [medline]
PHST- 2019/01/13 06:00 [entrez]
AID - db19-er03b [pii]
AID - 10.2337/db19-er03b [doi]
PST - ppublish
SO  - Diabetes. 2019 Mar;68(3):676. doi: 10.2337/db19-er03b. Epub 2019 Jan 11.

PMID- 30635274
OWN - NLM
STAT- In-Data-Review
LR  - 20190221
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 3
DP  - 2019 Mar
TI  - Erratum. Celastrol-Induced Weight Loss Is Driven by Hypophagia and Independent
      From UCP1. Diabetes 2018;67:2456-2465.
PG  - 676
LID - 10.2337/db19-er03a [doi]
FAU - Pfuhlmann, Katrin
AU  - Pfuhlmann K
FAU - Schriever, Sonja C
AU  - Schriever SC
FAU - Baumann, Peter
AU  - Baumann P
FAU - Kabra, Dhiraj G
AU  - Kabra DG
FAU - Harrison, Luke
AU  - Harrison L
FAU - Mazibuko-Mbeje, Sithandiwe E
AU  - Mazibuko-Mbeje SE
FAU - Contreras, Raian E
AU  - Contreras RE
FAU - Kyriakou, Eleni
AU  - Kyriakou E
FAU - Simonds, Stephanie E
AU  - Simonds SE
FAU - Tiganis, Tony
AU  - Tiganis T
FAU - Cowley, Michael A
AU  - Cowley MA
FAU - Woods, Stephen C
AU  - Woods SC
FAU - Jastroch, Martin
AU  - Jastroch M
FAU - Clemmensen, Christoffer
AU  - Clemmensen C
FAU - De Angelis, Meri
AU  - De Angelis M
FAU - Schramm, Karl-Werner
AU  - Schramm KW
FAU - Sattler, Michael
AU  - Sattler M
FAU - Messias, Ana C
AU  - Messias AC
FAU - Tschop, Matthias H
AU  - Tschop MH
FAU - Pfluger, Paul T
AU  - Pfluger PT
LA  - eng
PT  - Journal Article
PT  - Published Erratum
DEP - 20190111
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EFR - Diabetes. 2018 Nov;67(11):2456-2465. PMID: 30158241
EDAT- 2019/01/13 06:00
MHDA- 2019/01/13 06:00
CRDT- 2019/01/13 06:00
PHST- 2019/01/13 06:00 [pubmed]
PHST- 2019/01/13 06:00 [medline]
PHST- 2019/01/13 06:00 [entrez]
AID - db19-er03a [pii]
AID - 10.2337/db19-er03a [doi]
PST - ppublish
SO  - Diabetes. 2019 Mar;68(3):676. doi: 10.2337/db19-er03a. Epub 2019 Jan 11.

PMID- 30649360
OWN - NLM
STAT- Publisher
LR  - 20190116
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2019 Jan 11
TI  - Apnea hypopnea index during rapid eye movement sleep with diabetic retinopathy in
      patients with type 2 diabetes.
LID - 10.1210/jc.2018-00946 [doi]
AB  - Context: Recent studies based on home sleep apnea testing (HSAT) reported the
      potential association of sleep disordered breathing (SDB), such as obstructive
      sleep apnea (OSA), with diabetic retinopathy (DR). A few studies showed that the 
      apnea hypopnea index during rapid eye movement sleep (REM-AHI) is associated with
      glycated hemoglobin and hypertension, two known risk factors for DR. However,
      there are no studies that have evaluated the association of REM-AHI with DR
      because previous studies were based on HSAT. Objective: To determine the
      association of REM-AHI with DR. Design, Setting, and Patients: The study subjects
      were 131 patients with type 2 diabetes mellitus who underwent all-night
      polysomnography with >/=30 minutes of REM sleep and were free of heart failure or
      active lung disease and had not yet been treated for OSA. Logistic regression
      analysis was performed to determine the effect of REM-AHI on the prevalence of DR
      adjusted by several known risk factors for DR. Results: Quartile of REM-AHI was
      independently associated with DR [p=0.024, odds ratio (OR) and 95% confidence
      interval (95%CI) for Q2, 3.887 (0.737-20.495); Q3, 9.467 (1.883-47.588); Q4,
      12.898 (2.008-82.823), relative to Q1] whereas quartile of NREM-AHI was not
      (p=0.119). Similarly, continuous REM-AHI (OR, 2.875; 95%CI, 1.224-6.752; p=0.015)
      was independently associated with DR whereas NREM-AHI was not (p=0.107). In
      addition, AHI was independently associated with DR when controlling for several
      known risk factors for DR (p=0.043). Conclusion: REM-AHI was independently
      associated with DR. REM-AHI could be a potential risk factor for DR.
FAU - Nishimura, Akihiro
AU  - Nishimura A
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
FAU - Kasai, Takatoshi
AU  - Kasai T
AD  - Sleep Center, Toranomon Hospital, Tokyo, Japan.
AD  - Cardiovascular Respiratory Sleep Medicine, Department of Cardiovascular Medicine,
      Juntendo University Graduate School of Medicine, Tokyo, Japan.
FAU - Kikuno, Shota
AU  - Kikuno S
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
FAU - Nagasawa, Kaoru
AU  - Nagasawa K
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
FAU - Okubo, Minoru
AU  - Okubo M
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
FAU - Narui, Koji
AU  - Narui K
AD  - Sleep Center, Toranomon Hospital, Tokyo, Japan.
FAU - Mori, Yasumichi
AU  - Mori Y
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190111
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2019/01/17 06:00
MHDA- 2019/01/17 06:00
CRDT- 2019/01/17 06:00
PHST- 2018/04/30 00:00 [received]
PHST- 2019/01/08 00:00 [accepted]
PHST- 2019/01/17 06:00 [entrez]
PHST- 2019/01/17 06:00 [pubmed]
PHST- 2019/01/17 06:00 [medline]
AID - 5288013 [pii]
AID - 10.1210/jc.2018-00946 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2019 Jan 11. pii: 5288013. doi: 10.1210/jc.2018-00946.

PMID- 29897453
OWN - NLM
STAT- MEDLINE
DCOM- 20190104
LR  - 20190104
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 103
IP  - 7
DP  - 2018 Jul 1
TI  - Changes Over Time in Hepatic Markers Predict Changes in Insulin Sensitivity,
      beta-Cell Function, and Glycemia.
PG  - 2651-2659
LID - 10.1210/jc.2018-00306 [doi]
AB  - Context: Serum concentrations of liver enzymes and the hepatokine fetuin-A have
      been linked to the risk of type 2 diabetes, but their longitudinal impact on
      insulin resistance and beta-cell dysfunction is unclear. Objective: To evaluate
      the impact of changes over 2 years in fetuin-A and the liver enzymes alanine
      aminotransferase (ALT), aspartate aminotransferase (AST), and
      gamma-glutamyltransferase (GGT) on changes in insulin sensitivity, beta-cell
      function, and glycemia in women with varying degrees of previous gestational
      dysglycemia, reflecting a range of future diabetic risk.
      Design/Setting/Participants: In total, 336 women underwent glucose challenge test
      (GCT) and oral glucose tolerance test (OGTT) in pregnancy, followed by repeat
      OGTT and measurement of ALT/AST/GGT/fetuin-A at both 1 year and 3 years
      postpartum. The antepartum GCT/OGTT identified four gestational glucose tolerance
      groups: gestational diabetes (n = 104), gestational impaired glucose tolerance (n
      = 59), abnormal GCT with normal OGTT (n = 98), and normal GCT/OGTT (n = 75).
      Results: At 1 and 3 years postpartum, ALT, AST, GGT, and fetuin-A did not differ 
      across the four groups, but the intervening change in ALT/AST ratio was greater
      in the gestational dysglycemia groups (P = 0.05). Higher baseline ALT/AST (t =
      -1.99, P = 0.05) and fetuin-A (t = -3.17, P = 0.002) predicted lower insulin
      sensitivity (Matsuda) at 3 years, as did their respective changes from 1 to 3
      years (ALT/AST: t = -5.47, P < 0.0001; fetuin-A: t = -3.56, P = 0.0004). Change
      in ALT/AST predicted lower beta-cell function (t = -2.33, P = 0.02) and higher
      fasting glucose at 3 years (t = 2.55, P = 0.01). Moreover, baseline fetuin-A
      predicted prediabetes/diabetes at 3 years (OR, 1.38; 95% CI, 1.01 to 1.88).
      Conclusion: Circulating hepatic markers, particularly ALT/AST ratio and fetuin-A,
      track with changes in insulin sensitivity and beta-cell function, supporting a
      pathophysiologic basis in their prediction of diabetic risk.
FAU - Pinnaduwage, Lakmini
AU  - Pinnaduwage L
AD  - Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
FAU - Ye, Chang
AU  - Ye C
AD  - Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
FAU - Hanley, Anthony J
AU  - Hanley AJ
AD  - Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
AD  - Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada.
AD  - Department of Nutritional Sciences, University of Toronto, Toronto, Ontario,
      Canada.
FAU - Connelly, Philip W
AU  - Connelly PW
AD  - Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada.
AD  - Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto,
      Ontario, Canada.
FAU - Sermer, Mathew
AU  - Sermer M
AD  - Division of Obstetrics and Gynecology, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
FAU - Zinman, Bernard
AU  - Zinman B
AD  - Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
AD  - Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
FAU - Retnakaran, Ravi
AU  - Retnakaran R
AD  - Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
AD  - Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
LA  - eng
GR  - MOP-84206/CIHR/Canada
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (AHSG protein, human)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (alpha-2-HS-Glycoprotein)
RN  - EC 2.3.2.2 (gamma-Glutamyltransferase)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Alanine Transaminase/blood
MH  - Aspartate Aminotransferases/blood
MH  - Biomarkers/blood
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2
MH  - Diabetes, Gestational/blood
MH  - Female
MH  - Glucose Intolerance/*blood
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin Resistance/*physiology
MH  - Insulin-Secreting Cells/*physiology
MH  - Liver/*enzymology
MH  - Postpartum Period
MH  - Pregnancy
MH  - Prospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - alpha-2-HS-Glycoprotein/*metabolism
MH  - gamma-Glutamyltransferase/blood
EDAT- 2018/06/14 06:00
MHDA- 2019/01/05 06:00
CRDT- 2018/06/14 06:00
PHST- 2018/02/06 00:00 [received]
PHST- 2018/04/17 00:00 [accepted]
PHST- 2018/06/14 06:00 [pubmed]
PHST- 2019/01/05 06:00 [medline]
PHST- 2018/06/14 06:00 [entrez]
AID - 4980323 [pii]
AID - 10.1210/jc.2018-00306 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2018 Jul 1;103(7):2651-2659. doi: 10.1210/jc.2018-00306.

PMID- 30293768
OWN - NLM
STAT- MEDLINE
DCOM- 20190116
LR  - 20190116
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 392
IP  - 10160
DP  - 2018 Nov 17
TI  - Twice the benefits with twincretins?
PG  - 2142-2144
LID - S0140-6736(18)32466-8 [pii]
LID - 10.1016/S0140-6736(18)32466-8 [doi]
FAU - Stumvoll, Michael
AU  - Stumvoll M
AD  - Universitatsklinikum Leipzig and Helmholtz Institut fur Metabolismus, Adipositas 
      und Gefassforschung (HI-MAG), Leipzig, Germany.
FAU - Tschop, Matthias
AU  - Tschop M
AD  - Helmholtz Zentrum Munchen, Neuherberg, Germany; Technische Universitat Munchen,
      Munich 80333, Germany. Electronic address:
      matthias.tschoep@helmholtz-muenchen.de.
LA  - eng
PT  - Journal Article
PT  - Comment
DEP - 20181004
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - AIM
SB  - IM
CON - Lancet. 2018 Nov 17;392(10160):2180-2193. PMID: 30293770
MH  - *Diabetes Mellitus, Type 2
MH  - Drug Administration Schedule
MH  - *Glucagon-Like Peptide-1 Receptor
MH  - Humans
EDAT- 2018/10/09 06:00
MHDA- 2019/01/17 06:00
CRDT- 2018/10/09 06:00
PHST- 2018/09/21 00:00 [received]
PHST- 2018/09/28 00:00 [accepted]
PHST- 2018/10/09 06:00 [pubmed]
PHST- 2019/01/17 06:00 [medline]
PHST- 2018/10/09 06:00 [entrez]
AID - S0140-6736(18)32466-8 [pii]
AID - 10.1016/S0140-6736(18)32466-8 [doi]
PST - ppublish
SO  - Lancet. 2018 Nov 17;392(10160):2142-2144. doi: 10.1016/S0140-6736(18)32466-8.
      Epub 2018 Oct 4.